Hepatitis C: how has France limited the expenses related to new treatments? [0.03%]
法国如何限制与新型药物治疗丙型肝炎相关的费用？
Anne-Laure Mouterde,François Bocquet,Isabelle Fusier et al.
Anne-Laure Mouterde et al.
The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá [0.03%]
并存疾病对波哥大临床环境中HIV患者成本、效用及健康相关生活质量的影响
Mark Jm Van Duin,Rafael Conde,Ben Wijnen et al.
Mark Jm Van Duin et al.
Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. ...
A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis [0.03%]
维多珠单抗治疗中至重度活动性溃疡性结肠炎的成本效益分析的综述研究
Her Hsin Tsai,Christopher Black
Her Hsin Tsai
Vedolizumab is a novel humanised monoclonal IgG1 antibody gut selective anti-integrin specifically targeting α4β7 integrins in the gut and found to be efficacious in the treatment of ulcerative colitis. Areas covered: Research investigati...
Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C [0.03%]
索磷布韦维帕他韦治疗慢性丙型肝炎患者的报告结果和经济成果分析
Linda Henry,Zobair Younossi
Linda Henry
We used published literature from 2013-2016, to review data regarding the new all oral interferon and ribavirin free direct acting antiviral (DAA's) treatment regimens. Areas covered: Specifically, this paper will address DAA's clinical eff...
Corrigendum [0.03%]
勘误表
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland [0.03%]
芬兰重度抑郁症治疗切换至沃西汀与阿戈美拉丁、盐酸安非他酮缓释片、sertraline和文拉法辛缓释片的费用效用分析研究
Erkki Soini,Taru Hallinen,Mélanie Brignone et al.
Erkki Soini et al.
Background: To assess the cost-utility of vortioxetine versus relevant comparators (agomelatine, bupropion SR, sertraline, and venlafaxine XR) in the finnish setting in major depressive disorder (MDD) patients with inadeq...
Carl Rudolf Blankart,Ricarda Milstein,Meike Rybczynski et al.
Carl Rudolf Blankart et al.
Marfan syndrome is a rare multisystem disease of the connective tissue, which affects multiple organ systems. advances in healthcare have doubled the life-expectancy of patients over the past three decades. to date, there is no comprehensiv...
A scoping review of pediatric economic evaluation 1980-2014: do trends over time reflect changing priorities in evaluation methods and childhood disease? [0.03%]
1980-2014年儿科经济学评价的范围性综述：历时趋势反映评价方法和儿童疾病优先次序的变化吗？
Shannon M Sullivan,Kate Tsiplova,Wendy J Ungar
Shannon M Sullivan
Economic evaluations conducted in children have unique features compared to adults. Important developments in pediatric economic evaluation in recent years include new options for valuing health states for cost-utility analysis (CUA) and sh...
Sabine Vogler,Nina Zimmermann,Zaheer-Ud-Din Babar
Sabine Vogler
Background: In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compar...
Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry [0.03%]
影响制药行业建筑设计模式转变的宏观经济因素
Raphaela Marie Louisa Dierks,Olivier Bruyère,Jean-Yves Reginster et al.
Raphaela Marie Louisa Dierks et al.
Technological innovations, new regulations, increasing costs of drug productions and new demands are only few key drivers of a projected alternation in the pharmaceutical industry. The purpose of this review is to understand the macro econo...